Novo Nordisk hopes to launch experimental obesity drug this decade [Globe and Mail, The (Toronto, Canada)]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Globe and Mail, The
It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy. They would also likely have similar cardiac benefits as Wegovy. He hopes to launch them before the patents for semaglutide, Wegovy's active pharmaceutical ingredient (API), expire. “The current development plan is to finalize Cagrisema in both obesity and diabetes within the next two years, way before the patent expiry in semaglutide. “We believe it will be difficult for others to scale to the level we are currently scaling for semaglutide, and that basically means that even with the patent expiry, we could still serve a lot of patients with semaglutide, and complement with even more efficacious products like cagrisema and amycretin.” Wegovy: CEO Jorgensen said he expects a higher proportion of U.S. patients to stay on the weekly injection for more than one year as supply constraints ease. “Now we're focusing on really making sure that if y
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – CTLT, MGRC, CHRD, HRTGlobeNewswire
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) InvestigationAccesswire
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) InvestigationAccesswire
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) InvestigationAccesswire
- Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) InvestigationAccesswire
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/15/24 - Form DEFM14A
- 4/9/24 - Form S-8
- CTLT's page on the SEC website